A cross-sectional study to test equivalence of low- versus intermediate-flip angle dynamic susceptibility contrast MRI measures of relative cerebral blood volume in patients with high-grade gliomas at 1.5 Tesla field strength.
1.5 Tesla
dynamic susceptibility contrast MRI (DSC-MRI)
flip angle
glioma
standardization
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
02
2023
accepted:
21
08
2023
medline:
6
10
2023
pubmed:
6
10
2023
entrez:
6
10
2023
Statut:
epublish
Résumé
1.5 Tesla (1.5T) remain a significant field strength for brain imaging worldwide. Recent computer simulations and clinical studies at 3T MRI have suggested that dynamic susceptibility contrast (DSC) MRI using a 30° flip angle ("low-FA") with model-based leakage correction and no gadolinium-based contrast agent (GBCA) preload provides equivalent relative cerebral blood volume (rCBV) measurements to the reference-standard acquisition using a single-dose GBCA preload with a 60° flip angle ("intermediate-FA") and model-based leakage correction. However, it remains unclear whether this holds true at 1.5T. The purpose of this study was to test this at 1.5T in human high-grade glioma (HGG) patients. This was a single-institution cross-sectional study of patients who had undergone 1.5T MRI for HGG. DSC-MRI consisted of gradient-echo echo-planar imaging (GRE-EPI) with a low-FA without preload (30°/P-); this then subsequently served as a preload for the standard intermediate-FA acquisition (60°/P+). Both normalized (nrCBV) and standardized relative cerebral blood volumes (srCBV) were calculated using model-based leakage correction (C+) with IBNeuro™ software. Whole-enhancing lesion mean and median nrCBV and srCBV from the low- and intermediate-FA methods were compared using the Pearson's, Spearman's and intraclass correlation coefficients (ICC). Twenty-three HGG patients composing a total of 31 scans were analyzed. The Pearson and Spearman correlations and ICCs between the 30°/P-/C+ and 60°/P+/C+ acquisitions demonstrated high correlations for both mean and median nrCBV and srCBV. Our study provides preliminary evidence that for HGG patients at 1.5T MRI, a low FA, no preload DSC-MRI acquisition can be an appealing alternative to the reference standard higher FA acquisition that utilizes a preload.
Identifiants
pubmed: 37799462
doi: 10.3389/fonc.2023.1156843
pmc: PMC10548232
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1156843Subventions
Organisme : NCI NIH HHS
ID : R21 CA267139
Pays : United States
Informations de copyright
Copyright © 2023 Shiroishi, Weinert, Cen, Varghese, Dondlinger, Prah, Mendoza, Nazemi, Ameli, Amini, Shohas, Chen, Bigjahan, Zada, Chen, Neman-Ebrahim, Chang, Chow, Fan, Yang, Attenello, Ye, Kim, Patel, Lerner, Acharya, Hu, Quarles, Boxerman, Wu and Schmainda.
Déclaration de conflit d'intérêts
Author KS was employed IQ-AI Ltd and Imaging Biometrics LLC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Radiology. 2008 Nov;249(2):601-13
pubmed: 18780827
J Neurooncol. 2015 May;122(3):497-505
pubmed: 25773062
AJNR Am J Neuroradiol. 2015 Jun;36(6):E41-51
pubmed: 25907520
AJNR Am J Neuroradiol. 2019 Apr;40(4):626-633
pubmed: 30923088
Magn Reson Med. 1999 Dec;42(6):1072-81
pubmed: 10571928
Magn Reson Med. 1990 Jun;14(3):538-46
pubmed: 2355835
AJNR Am J Neuroradiol. 2018 Nov;39(11):1981-1988
pubmed: 30309842
Magn Reson Med. 2000 Jun;43(6):845-53
pubmed: 10861879
AJNR Am J Neuroradiol. 2012 Jan;33(1):69-76
pubmed: 22095961
Tomography. 2017 Mar;3(1):41-49
pubmed: 28584878
AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32
pubmed: 15502131
Magn Reson Med. 1990 May;14(2):249-65
pubmed: 2345506
Neuro Oncol. 2015 Aug;17(8):1148-56
pubmed: 25646027
AJNR Am J Neuroradiol. 2012 Jun;33(6):1081-7
pubmed: 22322605
Magn Reson Med. 2010 Sep;64(3):907-13
pubmed: 20806381
Neuro Oncol. 2015 Sep;17(9):1188-98
pubmed: 26250565
AJNR Am J Neuroradiol. 2011 Feb;32(2):382-7
pubmed: 21252041
Neuro Oncol. 2014 Jun;16(6):880-8
pubmed: 24431219
AJNR Am J Neuroradiol. 2015 Sep;36(9):1654-61
pubmed: 26066626
Neuro Oncol. 2012 Jul;14(7):919-30
pubmed: 22561797
AJNR Am J Neuroradiol. 2017 Mar;38(3):478-484
pubmed: 28034995